RNS Number : 8477U Renalytix AI PLC 03 August 2020 Renalytix AI plc ("RenalytixAI", the "Company") KidneyIntelX in Multi-Center Study to Monitor and Predict Kidney Risk in COVID-19 Patients Surge in Chronic Kidney Disease and Kidney Failure Expected Post-COVID-19 Mount Sinai-Led Study
RNS Number : 8003U Renalytix AI PLC 31 July 2020 Renalytix AI plc (the "Company") Total Voting Rights For the purposes of DTR5.6.1R of the Transparency Directive, the Company notifies the market of the following: As of 31 July 2020 , the Company's issued and fully paid share capital
NEW YORK, July 27, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“ RenalytixAI ” or the “ Company ”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower
RNS Number : 0885U Renalytix AI PLC 27 July 2020 Not for release, publication or distribution, in whole or in part, in or into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction Renalytix AI plc Over allotment option exercise
NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“ RenalytixAI ” or the “ Company ”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower
RNS Number : 6782T Renalytix AI PLC 21 July 2020 Renalytix AI plc Closing of Global Offering and resulting total voting rights Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX) (" RenalytixAI " or the " Company "), an artificial intelligence -enabled in vitro diagnostics company,
RNS Number : 3256T Renalytix AI PLC 17 July 2020 This announcement contains inside information Not for release, publication or distribution, in whole or in part, in or into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction
NEW YORK, July 16, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (“ RenalytixAI ” or the “ Company ”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs,
Download full announcement Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, today announces the commencement of an underwritten
Download full announcement Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that all resolutions proposed at the
